COVID-19 Forum, Information, Studies, Treatments
COVID-19 Coronavirus => COVID-19 Early Stage Outpatient Studies and Trials => Topic started by: admin on November 18, 2020, 11:34:23 AM
-
https://247wallst.com/healthcare-business/2020/10/07/taiwan-liposome-gets-the-go-ahead-for-a-hydroxychloroquine-covid-19-study/
Taiwan Liposome Gets the Go-Ahead for a Hydroxychloroquine COVID-19 Study
Chris Lange
October 7, 2020 11:32 am
Taiwan Liposome Co. Ltd. (NASDAQ: TLC) shares shot up on Wednesday after the firm announced that it would be able to move forward with its COVID-19 trial that uses hydroxychloroquine. In the past, hydroxychloroquine has been viewed as a controversial drug in terms of evaluating its efficacy in treating COVID-19, but now there seems to be a definitive ruling on it—at least in Australia and Taiwan.
In terms of the specifics, the company announced the receipt of ethical and scientific approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for the company’s Phase 1 clinical trial of TLC19 hydroxychloroquine liposome inhalation suspension for COVID-19.
Much more:
https://247wallst.com/healthcare-business/2020/10/07/taiwan-liposome-gets-the-go-ahead-for-a-hydroxychloroquine-covid-19-study/
I found their website. I wonder why they felt compelled to cite the deadly dosages from the WHO and UK HCQ trials and false information from the FDA, in order to sell their product, since it seems completely unnecessary.
https://www.tlcbio.com/en-global/pipeline/index/Infectious/TLC19